Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis

Young Nam Kwon, MD, MSc, Patrick J. Waters, PhD, Moonhang Kim, PhD, Youn Soo Choi, PhD, Jin Wook Kim, MD, PhD, Jung-Joon Sung, MD, PhD, Sung-Hye Park, MD, PhD, and Sung-Min Kim, MD, PhD

Neurol Neuroimmunol Neuroinflamm 2019;6:e600. doi:10.1212/NXI.0000000000000600

Correspondence

Dr. Kim
sueh916@gmail.com
or Dr. Park
shparknp@snu.ac.kr

An inflammatory demyelinating disease of the CNS with antibody against myelin oligodendrocyte glycoprotein (MOG-IgG) is now accepted as a discrete disease category of MOG encephalomyelitis (MOG-EM).¹ Previous case studies described abundant accumulation of phagocytic cells (either Iba1⁺ and/or CD68⁺) at the active demyelinating lesions of MOG-EM.^{2–5} However, both Iba1 and CD68 can be expressed in either the microglia or macrophage.⁶ Recently, transmembrane protein 119 (TMEM119) has been proposed to be a reliable microglial marker that discriminates resident microglia from blood-derived macrophages in the inflamed human brain.⁶

Here, we discuss the immunohistochemical findings in a patient with MOG-EM using a specific marker for microglia, TMEM119.⁶

Case report

A 34-year-old male patient presented with sudden disorientation in September 2018. The neurologic examination showed disturbed consciousness with a Mini-Mental State Examination score of 17. Brain MRI showed multiple enhancing and T2 high signal intensity (HSI) lesions in both periventricular and deep white matter of the cerebrum, cerebellum, and upper medulla oblongata (figure, A). A CSF analysis demonstrated a cell count of 20 cells/ μ L (18 lymphocytes) and a slightly elevated protein level (50 mg/dL). The oligoclonal bands were positive, and IgG index was 0.61. Whole-body 18F-fluorodeoxyglucose PET revealed multifocal white matter lesions with mild hypermetabolism suggesting active inflammation rather than the malignancy. Initial EEG showed no epileptiform discharge. Serum fluorescent antinuclear antibody, antineutrophil cytoplasmic antibody, human T-cell lymphotropic virus antibody, cryoglobulin, anticardiolipin antibody, anti- β_2 -glycoprotein 1 antibody, and aquaporin-4 antibody were all negative. CSF cytology test showed no evidence of malignant cell. We suspected acute disseminated encephalomyelitis (ADEM) at first, and high-dose IV methylprednisolone (IVMP, 1 g for 5 days) following oral prednisolone (60 mg/d) were administered. As the follow-up brain MRI revealed improvement in T2 HSI lesion volume, we gradually tapered out prednisolone over 1 month.

Two weeks after discontinuation of prednisolone (2 months after first attack), he developed the patient returned with acute confusion and a bilateral tingling sensation below the T6 sensory dermatome level. Spinal cord imaging showed a diffuse contiguous T2 HSI lesion in T3 to T5. Brain MRI revealed increasing multiple T2 HSI and enhanced lesions on the right temporoparietal white matter, right occipital lobe, and both high frontoparietal lobes suggesting

From the Department of Neurology (Y.N.K., J.-J.S., S.-M.K.), Seoul National University Hospital, Republic of Korea; Department of Neurology (Y.N.K.), Seoul National University Seoul Metropolitan Government Boramae Medical Center, Republic of Korea; Department of Medicine (Y.N.K.), Graduate School, Kyung Hee University, Republic of Korea; Neuroimmunology Group (P.J.W.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; Biomedical Research Institute (M.K.), Seoul National University Hospital, Republic of Korea; Department of Medicine (Y.S.C.), Seoul National University, College of Medicine, Republic of Korea; Department of Neurosurgery (J.W.K.), Seoul National University Hospital, Republic of Korea; Department of Neurology (J.-J.S., S.-M.K.), Neuroscience Research Institute, Seoul National University, College of Medicine, Seoul, Republic of Korea; and Department of Pathology (S.-H.P.), Seoul National University, College of Medicine, Seoul, Republic of Korea.

Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

The Article Processing Charge was funded by the authors.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

(A) His initial brain MRI showed multiple enhancing and T2 HSI lesions in both periventricular and deep white matter of the cerebrum, cerebellum, and upper medulla oblongata at first attack. The right parietal white matter was almost preserved at first attack (yellow circles). (B) Follow-up brain MRI, taken 2 months after first attack, revealed diffuse contiguous spinal T2 HSI lesion in T3–T5 spinal cord and increased number and extent of multiple T2 in his brain. Stereotactic brain biopsy was performed at gadolinium-enhancing lesion at the right parietal lobe (yellow circles). (C) The lesion is heavily infiltrated by foamy phagocytic cells with perivascular lymphocytic infiltration and reactive gliosis (arrows) (H&E stain). (D and E) Luxol fast blue and myelin basic protein stains show nearly complete demyelination. (F and G) The demyelinating area is heavily infiltrated by CD68⁺ and CD163⁺ foamy macrophages (Gitter cells), (H) but only few of them were positive for TMEM119. (I and J) The CD3 and CD8 delineate parenchymal T-cell and cytotoxic T-cell infiltration in the brain parenchyma and perivascular area. (K) However, the CD20 demonstrates perivascular B-cell infiltration. (L and M) The MOG-IgG assay result in healthy control and this patient. (N) TMEM119 staining in a positive control; brain tissue from a patient with glioblastoma; Magnification bars: 200 μ m. LFB = luxol fast blue; MBP = myelin basic protein; MOG = myelin oligodendrocyte glycoprotein; TMEM119 = transmembrane protein 119.

aggravated state of demyelinating disease or malignancy (figure, B). Because of diagnostic uncertainty, a stereotactic brain biopsy was performed in gadolinium-enhancing lesion of the right parietal lobe in early November 2018. He was treated again with IVMP. Serum MOG-IgG1 antibodies were detected by flow cytometry as described previously (figure, L and M).⁷

The neuropathology revealed severe demyelination with diffuse infiltration of the foamy CD68⁺ phagocytic cells, focal mild perivascular lymphocytic infiltration, reactive astrogliosis, and a few Creutzfeldt cells. CD68⁺ cells were abundant in diffuse parenchymal lesion, but all of them were negative for TMEM119. Many of CD3⁺ or CD8⁺ T cells were observed in the brain parenchyma and perivascular area, whereas CD20⁺ B cells were observed only in the perivascular area (figure,

C–K, and N). Brain tissue from a patient with glioblastoma was used as a positive control for TMEM119 staining, which revealed abundant TMEM119-positive cells.

Discussion

We report a case showing histopathologic characteristics of MOG-EM focusing on the origin of phagocytic cells. To identify the origin of these abundant phagocytic cells can be important in understanding the pathogenesis of MOG-IgG-associated disease. Our patient presented with an ADEM-like disease, and his neuropathologic findings revealed severe demyelination with infiltration of CD68⁺ TMEM119[−] macrophages, T cells in the brain parenchyma, perivascular B cells, and absence of TMEM119⁺ microglia.

There are a few previous biopsy studies describing the histopathology in patients with MOG-EM, which showed inflammatory demyelination.^{2–5} Although others did not distinguish microglia from macrophage, Ikeda et al.⁵ proposed that the Iba-1⁺ cells in the brain lesion of a patient with MOG-EM were microglia based on cell morphology. Nevertheless, the morphology of microglia/macrophage can change according to external signals with pathogen and damage-associated signals. Recently, TMEM119 has been used as a marker that can distinguish brain resident microglia from blood-derived macrophages in the inflamed human brain tissue.⁶ Our data, using this marker, suggest that the CD68⁺ TMEM119[–] cells in our MOG-EM patient's brain tissue are active macrophages recruited from the peripheral circulations. This finding can be important in understanding the pathogenesis and in developing the treatment strategy of MOG-EM. However, the ratio of macrophage/microglia in the pathology of IDD can depend on the stage of the biopsied lesion,⁸ the expression of TMEM119 on microglia can also be downregulated on its activation,⁶ and further studies with larger samples including very early lesions are needed for the exact pathophysiology of MOG-EM.

In conclusion, we identified that macrophages rather than the microglia were the major phagocytic cells in the active demyelinating lesions of MOG-EM. Further studies on the detailed immune mechanism of these abundant macrophages infiltration/recruitment are needed.

Acknowledgment

The control tissue of glioblastoma was obtained from the Brain Bank of the Seoul National University Hospital and Center for Medical Innovation. This study was conducted according to the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital (IRB No. H-1812-136-997).

Study funding

This work was partly supported by grant no. HI17C0335 from the Korea Health Industry Development Institute Research fund.

Disclosure

All authors report no disclosures. Go to Neurology.org/NN for full disclosures.

Publication history

Received by *Neurology: Neuroimmunology & Neuroinflammation* May 8, 2019. Accepted in final form June 18, 2019.

Appendix Authors

Name	Location	Role	Contribution
Young Nam Kwon, MD, MSc	Seoul National University Hospital, Seoul, Republic of Korea	Author	Drafting the manuscript; data acquisition and analysis; and read and approved the final manuscript

Appendix (continued)

Name	Location	Role	Contribution
Patrick J. Waters, PhD	John Radcliffe Hospital, Oxford, UK	Author	Data acquisition and analysis; critical reading of the manuscript; and read and approved the final manuscript
Moonhang Kim, PhD	Seoul National University Hospital, Seoul, Republic of Korea	Author	Data acquisition and analysis; read and approved the final manuscript
Youn Soo Choi, PhD	Seoul National University College of Medicine, Seoul, Republic of Korea	Author	Data acquisition and analysis; critical reading of the manuscript; and read and approved the final manuscript
Jin Wook Kim, MD, PhD	Seoul National University Hospital, Seoul, Republic of Korea	Author	Data acquisition and analysis and read and approved the final manuscript
Jung-Joon Sung, MD, PhD	Seoul National University Hospital, Seoul, Republic of Korea	Author	Critical reading of the manuscript and read and approved the final manuscript
Sung-Hye Park, MD, PhD	Seoul National University Hospital, Seoul, Republic of Korea	Co-corresponding author	Study conception and design; data acquisition and analysis; statistical analysis; critical reading of the manuscript; and read and approved the final manuscript
Sung-Min Kim, MD, PhD	Seoul National University Hospital, Seoul, Republic of Korea	Guarantor and corresponding author	Study conception and design; drafting of the manuscript; data acquisition and analysis; critical reading of the manuscript; and read and approved the final manuscript

References

- Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. *J Neuroinflammation* 2018;15:134.
- Spadaro M, Gerdes LA, Mayer MC, et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis. *Ann Clin Transl Neurol* 2015;2:295–301.
- Körtvélyessy P, Breu M, Pawlitzki M, et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e335. doi:10.1212/NXI.0000000000000335.
- Fujimori J, Takai Y, Nakashima I, et al. Bilateral frontal cortex encephalitis and paraparesis in a patient with anti-MOG antibodies. *J Neurol Neurosurg Psychiatry* 2017;88:534–536.
- Ikeda T, Yamada K, Ogawa R, et al. The pathological features of MOG antibody-positive cerebral cortical encephalitis as a new spectrum associated with MOG antibodies: a case report. *J Neurol Sci* 2018;392:113–115.
- Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H. Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis. *Brain* 2017;140:1900–1913.
- Lee HJ, Kim B, Waters P, et al. Chronic relapsing inflammatory optic neuropathy (CRION): a manifestation of myelin oligodendrocyte glycoprotein antibodies. *J Neuroinflammation* 2018;15:302.
- Metz I, Weigand SD, Popescu BF, et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. *Ann Neurol* 2014;75:728–738.

Neurology® Neuroimmunology & Neuroinflammation

Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis

Young Nam Kwon, Patrick J. Waters, Moonhang Kim, et al.

Neurol Neuroimmunol Neuroinflamm 2019;6;

DOI 10.1212/NXI.0000000000000600

This information is current as of August 1, 2019

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.

Updated Information & Services	including high resolution figures, can be found at: http://nn.neurology.org/content/6/5/e600.full.html
References	This article cites 8 articles, 1 of which you can access for free at: http://nn.neurology.org/content/6/5/e600.full.html##ref-list-1
Citations	This article has been cited by 2 HighWire-hosted articles: http://nn.neurology.org/content/6/5/e600.full.html##otherarticles
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Acute disseminated encephalomyelitis http://nn.neurology.org/cgi/collection/acute_disseminated_encephalomyelitis All Clinical Neurology http://nn.neurology.org/cgi/collection/all_clinical_neurology All Demyelinating disease (CNS) http://nn.neurology.org/cgi/collection/all_demyelinating_disease_cns All Immunology http://nn.neurology.org/cgi/collection/all_immunology Autoimmune diseases http://nn.neurology.org/cgi/collection/autoimmune_diseases
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://nn.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://nn.neurology.org/misc/addir.xhtml#reprintsus

Neurol Neuroimmunol Neuroinflamm is an official journal of the American Academy of Neurology. Published since April 2014, it is an open-access, online-only, continuous publication journal. Copyright Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.. All rights reserved. Online ISSN: 2332-7812.